Azithramycine
Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.
Cross Reference
Introduction
To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Azithramycine?
Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (156)
- Clin. Infect. Dis. (64)
- J. Antimicrob. Chemother. (50)
- Others (435)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Azithramycine
PubChem Associated disorders and diseases
What pathways are associated with Azithramycine
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Azithramycine?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (66)
- J. Antimicrob. Chemother. (25)
- Clin. Infect. Dis. (13)
- Others (151)
| Location | Cross reference | Weighted score | Related literatures |
|---|
What functions are associated with Azithramycine?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Azithramycine?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
What genes are associated with Azithramycine?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (44)
- J. Antimicrob. Chemother. (18)
- Clin. Infect. Dis. (10)
- Others (126)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with Azithramycine?
Mouse Model
Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).
Knock-out
Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).
Tissue Model
Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
NCBI Entrez Crosslinks
All references with Azithramycine
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Arrieta A et al. | High-dose azithromycin versus high-dose amoxicillin-clavulanate for treatment of children with recurrent or persistent acute otitis media. | 2003 | Antimicrob. Agents Chemother. | pmid:14506028 |
| Nilius AM et al. | Comparative in vitro activity of ABT-773, a novel antibacterial ketolide. | 2001 | Antimicrob. Agents Chemother. | pmid:11408246 |
| Maves RC et al. | Antimicrobial susceptibility of Brucella melitensis isolates in Peru. | 2011 | Antimicrob. Agents Chemother. | pmid:21199926 |
| Ishida K et al. | In vitro and in vivo activities of macrolides against Mycoplasma pneumoniae. | 1994 | Antimicrob. Agents Chemother. | pmid:8031048 |
| Hauser C et al. | In vitro activity of fosfomycin alone and in combination with ceftriaxone or azithromycin against clinical Neisseria gonorrhoeae isolates. | 2015 | Antimicrob. Agents Chemother. | pmid:25547354 |
| Nash KA and Inderlied CB | Genetic basis of macrolide resistance in Mycobacterium avium isolated from patients with disseminated disease. | 1995 | Antimicrob. Agents Chemother. | pmid:8592991 |
| Bohte R et al. | Levels of azithromycin and alpha-1 acid glycoprotein in serum in patients with community-acquired pneumonia. | 1995 | Antimicrob. Agents Chemother. | pmid:8593024 |
| Salman S et al. | Pharmacokinetic properties of azithromycin in pregnancy. | 2010 | Antimicrob. Agents Chemother. | pmid:19858250 |
| Dubois J et al. | In vitro and intracellular activities of peptide deformylase inhibitor GSK1322322 against Legionella pneumophila isolates. | 2015 | Antimicrob. Agents Chemother. | pmid:25348534 |
| Maezono H et al. | Antibiofilm effects of azithromycin and erythromycin on Porphyromonas gingivalis. | 2011 | Antimicrob. Agents Chemother. | pmid:21911560 |
| Clark C et al. | In vitro selection of resistance in Haemophilus influenzae by amoxicillin-clavulanate, cefpodoxime, cefprozil, azithromycin, and clarithromycin. | 2002 | Antimicrob. Agents Chemother. | pmid:12183253 |
| Yamada K et al. | Azithromycin attenuates lung inflammation in a mouse model of ventilator-associated pneumonia by multidrug-resistant Acinetobacter baumannii. | 2013 | Antimicrob. Agents Chemother. | pmid:23733468 |
| Jacobs MR et al. | Study design questions in treatment of children with acute otitis media. | 2004 | Antimicrob. Agents Chemother. | pmid:15241848 |
| Blandizzi C et al. | Distribution of azithromycin in plasma and tonsil tissue after repeated oral administration of 10 or 20 milligrams per kilogram in pediatric patients. | 2002 | Antimicrob. Agents Chemother. | pmid:11959610 |
| Moon JE et al. | Efficacy of macrolides and telithromycin against leptospirosis in a hamster model. | 2006 | Antimicrob. Agents Chemother. | pmid:16723556 |
| Steele-Moore L et al. | In vitro activities of clarithromycin and azithromycin against clinical isolates of Mycobacterium avium-M. intracellulare. | 1999 | Antimicrob. Agents Chemother. | pmid:10383373 |
| Bogdanovich T et al. | Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis. | 2006 | Antimicrob. Agents Chemother. | pmid:16723565 |
| Kosowska-Shick K et al. | Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents. | 2006 | Antimicrob. Agents Chemother. | pmid:16723567 |
| Carannante A et al. | Changing antimicrobial resistance profiles among Neisseria gonorrhoeae isolates in Italy, 2003 to 2012. | 2014 | Antimicrob. Agents Chemother. | pmid:25070110 |
| Zhang Y et al. | Novel Detection Strategy To Rapidly Evaluate the Efficacy of Antichlamydial Agents. | 2017 | Antimicrob. Agents Chemother. | pmid:27855081 |
| Waites KB et al. | In Vitro Activities of Lefamulin and Other Antimicrobial Agents against Macrolide-Susceptible and Macrolide-Resistant Mycoplasma pneumoniae from the United States, Europe, and China. | 2017 | Antimicrob. Agents Chemother. | pmid:27855075 |
| Shimuta K et al. | Antimicrobial resistance and molecular typing of Neisseria gonorrhoeae isolates in Kyoto and Osaka, Japan, 2010 to 2012: intensified surveillance after identification of the first strain (H041) with high-level ceftriaxone resistance. | 2013 | Antimicrob. Agents Chemother. | pmid:23939890 |
| D'Ignazio J et al. | Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired Pneumonia in adults. | 2005 | Antimicrob. Agents Chemother. | pmid:16189077 |
| Jensen JS et al. | In vitro activity of the new fluoroketolide solithromycin (CEM-101) against macrolide-resistant and -susceptible Mycoplasma genitalium strains. | 2014 | Antimicrob. Agents Chemother. | pmid:24637681 |
| Bielaszewska M et al. | Effects of antibiotics on Shiga toxin 2 production and bacteriophage induction by epidemic Escherichia coli O104:H4 strain. | 2012 | Antimicrob. Agents Chemother. | pmid:22391549 |
| Nagai K et al. | Activities of a new fluoroketolide, HMR 3787, and its (des)-fluor derivative RU 64399 compared to those of telithromycin, erythromycin A, azithromycin, clarithromycin, and clindamycin against macrolide-susceptible or -resistant Streptococcus pneumoniae and S. pyogenes. | 2001 | Antimicrob. Agents Chemother. | pmid:11600391 |
| Klemens SP and Cynamon MH | Intermittent azithromycin for treatment of Mycobacterium avium infection in beige mice. | 1994 | Antimicrob. Agents Chemother. | pmid:7986001 |
| Andersen SL et al. | Efficacy of azithromycin as a causal prophylactic agent against murine malaria. | 1994 | Antimicrob. Agents Chemother. | pmid:7986022 |
| Pruul H and McDonald PJ | Potentiation of antibacterial activity of azithromycin and other macrolides by normal human serum. | 1992 | Antimicrob. Agents Chemother. | pmid:1317141 |
| Mandell GL and Coleman EJ | Activities of antimicrobial agents against intracellular pneumococci. | 2000 | Antimicrob. Agents Chemother. | pmid:10952618 |
| Brown BA et al. | Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. | 1992 | Antimicrob. Agents Chemother. | pmid:1317144 |
| Welsh LE et al. | In vitro evaluation of activities of azithromycin, erythromycin, and tetracycline against Chlamydia trachomatis and Chlamydia pneumoniae. | 1992 | Antimicrob. Agents Chemother. | pmid:1318677 |
| Freeman CD et al. | Intracellular and extracellular penetration of azithromycin into inflammatory and noninflammatory blister fluid. | 1994 | Antimicrob. Agents Chemother. | pmid:7840585 |
| Nagai K et al. | Susceptibility to telithromycin in 1,011 Streptococcus pyogenes isolates from 10 central and Eastern European countries. | 2002 | Antimicrob. Agents Chemother. | pmid:11796375 |
| Su XH et al. | Multidrug-Resistant Neisseria gonorrhoeae Isolates from Nanjing, China, Are Sensitive to Killing by a Novel DNA Gyrase Inhibitor, ETX0914 (AZD0914). | 2015 | Antimicrob. Agents Chemother. | pmid:26482313 |
| Agacfidan A et al. | In vitro activity of azithromycin (CP-62,993) against Chlamydia trachomatis and Chlamydia pneumoniae. | 1993 | Antimicrob. Agents Chemother. | pmid:8239579 |
| Tomazic J et al. | In vivo administration of azithromycin affects lymphocyte activity in vitro. | 1993 | Antimicrob. Agents Chemother. | pmid:8239585 |
| Rakita RM et al. | Intracellular activity of azithromycin against bacterial enteric pathogens. | 1994 | Antimicrob. Agents Chemother. | pmid:7810998 |
| Cantin L and Chamberland S | In vitro evaluation of the activities of azithromycin alone and combined with pyrimethamine against Toxoplasma gondii. | 1993 | Antimicrob. Agents Chemother. | pmid:8239619 |
| Meyer AP et al. | Uptake of azithromycin by human monocytes and enhanced intracellular antibacterial activity against Staphylococcus aureus. | 1993 | Antimicrob. Agents Chemother. | pmid:8285612 |
| Imamura Y et al. | Azithromycin exhibits bactericidal effects on Pseudomonas aeruginosa through interaction with the outer membrane. | 2005 | Antimicrob. Agents Chemother. | pmid:15793115 |
| Shima K et al. | Impact of a low-oxygen environment on the efficacy of antimicrobials against intracellular Chlamydia trachomatis. | 2011 | Antimicrob. Agents Chemother. | pmid:21321137 |
| Chinh NT et al. | Pharmacokinetics and ex vivo antimalarial activity of artesunate-azithromycin in healthy volunteers. | 2011 | Antimicrob. Agents Chemother. | pmid:21730120 |
| Wind CM et al. | A Case-Control Study of Molecular Epidemiology in Relation to Azithromycin Resistance in Neisseria gonorrhoeae Isolates Collected in Amsterdam, the Netherlands, between 2008 and 2015. | 2017 | Antimicrob. Agents Chemother. | pmid:28373191 |
| Karlowsky JA et al. | Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States. | 2003 | Antimicrob. Agents Chemother. | pmid:12760850 |
| Yamaguchi H et al. | Chlamydia pneumoniae resists antibiotics in lymphocytes. | 2003 | Antimicrob. Agents Chemother. | pmid:12760877 |
| Kutlin A et al. | Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous-infection Model. | 2002 | Antimicrob. Agents Chemother. | pmid:11796350 |
| Jacks SS et al. | In vitro susceptibilities of Rhodococcus equi and other common equine pathogens to azithromycin, clarithromycin, and 20 other antimicrobials. | 2003 | Antimicrob. Agents Chemother. | pmid:12709351 |
| Matzneller P et al. | Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy. | 2013 | Antimicrob. Agents Chemother. | pmid:23357769 |
| Patel KB et al. | Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. | 1996 | Antimicrob. Agents Chemother. | pmid:8891147 |